ArticleMedicine2026

Palivizumab prophylaxis and risk of RSV infection among moderate-to-late preterm infants: A nationwide Korean cohort study from 2018 to 2022.

Hyejin So et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.